<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789564</url>
  </required_header>
  <id_info>
    <org_study_id>qgeng-2021-2-16</org_study_id>
    <nct_id>NCT04789564</nct_id>
  </id_info>
  <brief_title>Predictors of CMR Related Parameters in STEMI Patients After Primary PCI and Its Correlation With Adverse Left Ventricular Remodeling and Major Adverse Cardiovascular Events</brief_title>
  <official_title>Predictors of CMR Related Parameters: Intramyocardial Hemorrhage, Microvascular Obstruction , Area at Risk and Strain Related Parameters, and Their Effects on Adverse Ventricular Remodeling and MACEs in STEMI Patients After Primary PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qian geng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim to investigate the association of CMR measured parameters: infarct size (IS),&#xD;
      intramyocardial hemorrhage, microvascular obstruction , area at risk and CMR derived strain&#xD;
      parameters with the risk of all-cause mortality and MACEs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will enroll 800 patients with STEMI after PCI who were admitted to the Chinese&#xD;
      PLA General Hospital between January 2014 and December 2019. CMR was performed at 7 days and&#xD;
      6 months after primary PCI to assess the final infarction size(IS), microvascular obstruction&#xD;
      (MVO), intramyocardial hemorrhage(IMH), area at risk (AAR) and related strain parameters. All&#xD;
      patients will be followed up by 5 years after addimission index. Cardiovascular events&#xD;
      concluding stroke, repeat revascularization, rehospitalization for acute heart failure,&#xD;
      nonfatal myocardial infarction, and all cause death. All adverse clinical events as well as&#xD;
      study end points were monitored and adjudicated by the independent event committee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2014</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>follow up in five years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MACEs</measure>
    <time_frame>follow up in five years</time_frame>
    <description>Cardiovascular events concluding stroke, repeat revascularization, rehospitalization for acute heart failure, nonfatal myocardial infarction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct size</measure>
    <time_frame>7 days and 6 month after PCI</time_frame>
    <description>Myocardial infarct size is derived from MR delayed enhancement scan</description>
  </secondary_outcome>
  <enrollment type="Actual">800</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>cardiovascular magnetic resonance (CMR)</intervention_name>
    <description>Testing CMR on patients of 7 days and 6 months after myocardial infarction</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Investigators will enroll 800 patients with STEMI after PCI who were admitted to the&#xD;
        Chinese PLA General Hospital between January 2014 and January 2019. CMR was performed at 7&#xD;
        days and 6 months after primary PCI to assess the final infarction size, microvascular&#xD;
        obstruction (MVO), area at risk (AAR) and related strain parameters. All patients will be&#xD;
        followed up by 5 years after addimission index.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-80 years.&#xD;
&#xD;
          2. clinically diagnosed ST-segment elevation myocardial infarction.&#xD;
&#xD;
          3. Intended to undergo emergency PCI.&#xD;
&#xD;
          4. Voluntary enrollment and signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. cardiogenic shock, papillary muscle rupture, ventricular septal perforation, episodes&#xD;
             of ventricular tachycardia or ventricular fibrillation and post-electrical&#xD;
             resuscitation, 3rd degree AVB, and temporary pacemaker implantation before PCI.&#xD;
&#xD;
          2. LVEF â‰¤ 30%.&#xD;
&#xD;
          3. combined aortic coarctation.&#xD;
&#xD;
          4. presence of valvular heart disease, congenital heart disease and history of pulmonary&#xD;
             hypertension and other cardiomyopathies.&#xD;
&#xD;
          5. undergoing revascularization (PCI or CABG) within 6 months&#xD;
&#xD;
          6. contraindications to cardiovascular MRI.&#xD;
&#xD;
          7. current or within 3 months participation in other research studies.&#xD;
&#xD;
          8. Pregnant and lactating women.&#xD;
&#xD;
          9. those with severe mental impairment and unable to express their will&#xD;
&#xD;
         10. Patients with other significant abnormal signs, laboratory tests and clinical disease&#xD;
             are unsuitable for participation in the study accessed by clinicians.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chinese People's Liberation Army General Hospital</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Qian geng</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Intramyocardial Hemorrhage(IMH)</keyword>
  <keyword>Microvascular Obstruction(MVO)</keyword>
  <keyword>Area at Risk(AAR)</keyword>
  <keyword>CMR Related Strain Parameters</keyword>
  <keyword>ST-segment elevation myocardial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

